Truffle Capital raised €250M for its Bio MedTech Startup Fund with the purpose of creating a portfolio of MedTech startups from scratch and incubating them long enough to raise external capital or be positioned to exit. We are hiring a Chief Executive Officer for Truffle Capital’s portfolio company, Caranx Medical.
Successful Exit: Truffle Capital founded Symetis (TAVI) which was acquired by Boston Scientific for $435M.
We have partnered with Michel Therin, Operating Partner of Truffle Capital, to hire our CEO of Caranx Medical to lead R&D, product development, and portfolio strategies. This position will operate as a business line leader to drive the team through product development processes across multiple indications and will drive fundraising initiatives with the support of Truffle Capital.
This position will report directly to Michel Therin and will either relocate to Nice, France or be willing to travel to Nice two weeks per month.
Caranx Medical is seeking for a Chief Executive Officer who will work closely with the Board of Directors to provide the vision, strategy, leadership, program development expertise to ensure the transformation of Caranx Medical from an ‘early stage’ (POC/ IP) entity to a pre-market and then market ready stage company.
It is therefore essential that the CEO comes with a strong record in combining R&D operation, portfolio management experience and leadership with business strategy to ensure the future success of Caranx Medical.
The CEO shall achieve ambitious and breakthrough clinical outcomes as well as the complete and successful development of the technology and the establishment of a full-fledge operation. CEO’s and Board of Director’s goal will be to successfully achieve several rounds of fund raising up to the market entry through a strategic partnership or IPO.
Medtech senior leader – Engineer degree minimum, double background ie MD/PhD desirable – with an outstanding track-record in bringing innovative product from IP / POC stage to clinical / market stage, this should include the following
Medtech with successful experience in (by order of priority): 1- Capital equipment (1-Robotics, 2-imaging…) or 2- Implantable/invasive devices (1- cardio vascular, 2- endoscopy…)
End to end NPD / New Product Development expertise with demonstrated experience in overseeing critical activities and ensuring research and development commitments and related projects are fulfilled
Both clinical and engineering expertise on which to base rapid clinical use understanding, sound risk assessments and robust design control & development – this should notably involve a strong track-record in building and managing close working relations with KOL’s and Scientific Boards at international level
IP (intellectual property) development and strengthening for complex medical devices
In-depth command of clinical and regulatory path to gain market access both in USA (PMA/ de novo 510k) and Europe (CE mark, class III) – this implies experience in monitoring interactions with the European and US regulatory authorities
Capacity (or experience desirable) to lead successive fund raising through the lifecycle development of the platforms.
Candidate should have developed innovative and/or disruptive medical device/implant in scientifically and technically challenging applications (not incremental improvements or me-too products) in one of the following therapeutic areas: structural heart, vascular, soft tissue surgery, gastroenterology or robotic assisted interventions.
People leader who ensures that relevant personnel are hired, motivated and retained while continuing to strengthen Caranx Medical’s development, clinical and regulatory capabilities in line with the needs of its product program.
Capability to bring established professional relations and the know-how to deploy and lead a comprehensive network of external technical, scientific and clinical partners to put together resources necessary to the development program.
Capability to represent and be the voice of Caranx Medical in front of key stakeholders across the business and scientific international communities.
Full fluency English is mandatory, capabilities in French will be appreciated.
A predisposition to roll-up-the-sleeves and personally engage in the work at hand; comfortable working in the resource-constrained, fast-paced environment of early-stage companies.
Strong communication and influence skills with the ability and personal style to inspire confidence and work successfully with varied audiences including industry partners, the management team, the Board of Directors and the scientific community. Open and effective communicator, able to comfortably and effectively engage in discussions with scientists, clinicians, employees and other key stakeholders.
Caranx Medical is an early stage Medtech company created and financed by Truffle Capital, through its BioMedTech fund, with the objective to develop the next generation of endoluminal robots that will democratize fast growing but complex procedures in major clinical specialties such as structural heart diseases and obesity.
Founded in 2001 and based in Paris, Truffle Capital is an independent venture capital company focused on setting up and financing start-up companies with disruptive technologies, from inception to commercial stage, in life sciences and IT that have the potential to become market leaders.
Truffle Capital’s investments include Symetis (TAVI, sold to Boston Scientific), Vexim (vertebral implants, sold to Stryker) Carmat (Total artificial heart, currently in pivotal trials). With its BioMedTech fund, Truffle Capital has already created 6 companies, including Holistick Medical (PFO closure, technology licensed from Harvard & MIT), ArteDrone (microrobots for stroke) as well as Nanosive (Sun protection technology, licensed from YALE).
Founded end of 2020, Caranx Medical is developing smart robots that allows planification, navigation and execution of procedural steps in a semi-autonomous mode, under the supervision of the physician. Currently at a preclinical stage, Caranx is aiming its first in man end of 2024/early 2025 for a commercial launch staged from 2028 to 2030.
Co-Founder & CEO | Truffle Capital
Senior Partner | Truffle Capital
Operating Partner | Truffle Capital
Lifeblood Capital™ supports global MedTech Startups with Talent Acquisition and Fundraising Strategies. We build full-scale startup teams from Board and C-level executives to entry-level individual contributors and from early-stage R&D through multi-national commercialization phases.Approaching two decades of experience in the MedTech industry, our talent acquisition services and team-building efforts are the results of 2,000+ successful hires for 500+ companies in 6 continents. We have facilitated more than $220 million for MedTech startups with our fundraising strategies and global investor network.
People and money are the lifeblood capital of startups. Learn from our entrepreneurs and investors as we demystify raising and investing capital on our MedTech Money Podcast Series.